» Articles » PMID: 21664507

The Evolution of Combined Oral Contraception: Improving the Risk-to-benefit Ratio

Overview
Journal Contraception
Publisher Elsevier
Date 2011 Jun 14
PMID 21664507
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Since its introduction in 1960, the combined oral contraceptive (COC) pill has become one of the most widely and frequently used methods of contraception worldwide. Although highly effective, early COC formulations were associated with significant adverse effects and unacceptable cardiovascular risk. Improvements in tolerability and safety have been achieved, without compromises in effectiveness, primarily via hormone dosage reductions and the development of several new progestins. Multiphasic COCs and extended-/continuous-cycle COCs have also been introduced, although the clinical advantages of these formulations vs. traditional COCs have yet to be established. Inclusion of natural estrogens such as estradiol valerate and 17β-estradiol with selective progestins in new combinations that maintain good cycle control is the most recent evolutionary step designed to improve COC tolerability and safety. Vigorous research needs to continue to help guarantee that the unmet need for safe and effective contraception is satisfied in future generations.

Citing Articles

Evolution of Oral Contraceptive Pills.

Gandhi A, Supe P J Obstet Gynaecol India. 2024; 74(2):109-112.

PMID: 38707879 PMC: 11065849. DOI: 10.1007/s13224-024-01988-4.


Non-Hormonal Contraception.

Howard S, Benhabbour S J Clin Med. 2023; 12(14).

PMID: 37510905 PMC: 10381146. DOI: 10.3390/jcm12144791.


Toward an optimal contraception dosing strategy.

Gavina B, de Los Reyes V A, Olufsen M, Lenhart S, Ottesen J PLoS Comput Biol. 2023; 19(4):e1010073.

PMID: 37053167 PMC: 10101497. DOI: 10.1371/journal.pcbi.1010073.


Perception and use of reversible contraceptive methods in Germany: A social listening analysis.

Balakrishnan P, Kroiss C, Keskes T, Friedrich B Womens Health (Lond). 2023; 19:17455057221147390.

PMID: 36642972 PMC: 9846300. DOI: 10.1177/17455057221147390.


Oral Contraceptive and Glioma Risk: A Prospective Cohort Study and Meta-Analysis.

Shao C, Tang H, Wang X, He J, Wang P, Wu N Front Public Health. 2022; 10:878233.

PMID: 35910887 PMC: 9330220. DOI: 10.3389/fpubh.2022.878233.